Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03588754 · ClinicalTrials.gov registry record · Phase 2
Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?
A Phase 2 study of Alcohol Drinking, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03588754: Active Phase 2 study of Alcohol Drinking, sponsored by Yale University.
NCT03588754 is a Phase 2 study of Alcohol Drinking that is active but no longer recruiting, run by Yale University. The registered enrollment target is 20 participants, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03588754, a Phase 2 study of Alcohol Drinking, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
For this protocol, the investigators plan to conduct a pilot study evaluating the effect of propranolol on alcohol consumption. Using a parallel design, the investigators plan to randomize 20 non-treatment seeking adults with alcohol use disorders (DSM-5) to propranolol extended release (160mg/day or placebo; n=10 per cell) to evaluate whether propranolol reduces alcohol self-administered in the laboratory. Importantly, the investigators will evaluate whether propranolol counteracts stress-induced effects on alcohol self-administration. Following titration to steady state medication levels over a 2-week period, each subject will complete two laboratory sessions consisting of a well validated method for inducing stress or neutral/relaxing state (order counterbalanced), followed by a 2-hour alcohol self-administration paradigm known to be sensitive to medication effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-09-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
What the registry record for NCT03588754 still lists
NCT03588754 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Alcohol Drinking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03588754 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03588754 about?
NCT03588754 is a clinical study titled "Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?". For this protocol, the investigators plan to conduct a pilot study evaluating the effect of propranolol on alcohol consumption. Using a parallel design, the investigators plan to randomize 20 non-treatment seeking adults with alcohol use disorders (DSM-5) to propranolol extended release (160mg/day o...
What is the current status of trial NCT03588754?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-09-15. Estimated completion is 2026-02-28.
What conditions does trial NCT03588754 study?
This clinical trial studies the following conditions: Alcohol Drinking.
What interventions are being tested in trial NCT03588754?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG).
Who is sponsoring clinical trial NCT03588754?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03588754 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Drinking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03588754's enrollment target sits among peer trials
20 76th of 85 higher than 6 of 85 other Alcohol Drinking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Drinking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
Ketone Ester Intervention in Alcohol Use Disorder
RECRUITING · Phase 2
-
Effects Ketone Supplement and Alcohol on Brain Metabolism
RECRUITING · Phase 2
-
Effect of Nutritional Ketosis on Alcohol Metabolism
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Acute Effects of Ketone Supplement on Responses to Alcohol Challenge in Healthy Volunteers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI